Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 million in an upsized US initial public offering.
By Avalon Pernell · Bloomberg
Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 million in an upsized US initial public offering.